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Abstract
Familial amyloid polyneuropathy (FAP) type IV (FINNISH) is 
a rare clinical entity with challenging neuropathy and cosmetic 
deficits. Amyloidosis can affect peripheral sensory, motor, or 
autonomic nerves. Nerve lesions are induced by deposits of 
amyloid fibrils and treatment approaches for neuropathy are 
challenging. Involvement of cranial nerves and atrophy in facial 
muscles is a real concern in daily life of such patients. Currently, 
diagnosis of neuropathy can be made by electrodiagnostic 
studies and diagnosis of amyloidosis can be made by genetic 
testing or by detection of amyloid deposition in abdominal 
fat pad, rectal, or nerve biopsies. It is preferable to consider 
FAP as one of the differential diagnosis of a case presented 
with multiple cranial nerves symptoms. The authors present a 
case of familial amyloid polyneuropathy (FAP) type IV with 
severe involvement of multiple cranial nerves, peripheral limb 
neuropathy, and orthostatic hypotension.
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Introduction
Familial amyloid polyneuropathy (FAP) type IV (FINNISH) is 
a very rare life-threatening disorder and reported only in a 
few countries.1 FAPs transmitted as an autosomal dominant 
trait neurodegenerative disorder associated with extracellular 
deposition of amyloid fibrils, particularly in the peripheral nervous 
system.
There are several forms of hereditary amyloidosis 
associated with peripheral neuropathy.2 FAP is a progressive 
sensorimotor and autonomic neuropathy of adulthood onset. 
There is phenotypic and genetic heterogeneity among the 
different forms of FAPs. Mutations in the genes for transthyretin 
(prealbumin), apolipoprotein A1 or gelsolin are responsible for 
the various forms of FAP.2 FAP type IV is caused by mutations 
in the gelsolin gene.3 Diagnosis of amyloidosis can be made 
by genetic testing or by detection of amyloid deposition in 
abdominal fat pad, rectal, or nerve biopsies. We present the 
first case of familial amyloid polyneuropathy (FAP) type IV 
in an Iranian woman with severe involvement of multiple 
cranial nerves, peripheral limb neuropathy, and orthostatic 
hypotension.
Case Report
What’s Known
•	 Familial	 amyloid	 polyneuropathy	
(FAP) type IV (FINNISH) is a very rare 
life-threatening disorder transmitted as 
an autosomal dominant.
•	 This	neurodegenerative	disorder	is	
associated with extracellular deposition 
of	 amyloid	 fibrils,	 particularly	 in	 the	
peripheral nervous system. 
What’s New
•	 This	 case	 highlights	 one	 of	 the	
rare conditions that causes neuropathy, 
presenting mainly with facial muscle 
wasting.
•	 In	case	of	symptomatic	progressive	
multiple cranial nerve involvement 
and peripheral polyneuropathy, FAP 
should	be	considered	in	the	differential	
diagnosis.
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Case Presentation
A 27-year-old Iranian woman referred to the 
authors’ electrodiagnostic department with 
severe facial muscles atrophy causing cosmetic 
problems and avoidance of social activities. 
Her medical history was positive for familial 
amyloidosis diagnosed based on abdominal and 
rectal biopsies when she was in second grade. 
She had biopsies because of positive familial 
history of amyloidosis in her mother and older 
sister. She was symptom-free until 22 years of 
age. Her symptoms developed during 5 years. 
Symptoms developed with mild weakness during 
chewing food and progressed to severe facial 
muscle atrophy with cosmetic problems and mild 
tingling in feet. Soon after, she presented with 
dizziness during standing up from sitting position 
and blurred vision.
At examination, she showed bilateral 
severe facial muscle and tongue atrophy and 
fasciculation of the tongue and left side ptosis. 
Her appearance was sad, with drooping eyelids, 
and hanging skin of the face (figure 1). She 
also showed generalized hyporeflexia without 
muscular weakness or atrophy in the limbs. 
Corneal sensation was decreased and sensation 
was impaired on face with mild sensory 
disturbances in feet accompanied by mild 
sensory ataxia. Slit lamp examination revealed 
multiple streaks on the cornea (corneal lattice), 
which was compatible with a characteristic 
feature of FAP type IV. The jaw reflex was 
absent and speech was incomprehensible. We 
observed orthostatic hypotension of 45 mmHg. 
No abnormal findings were observed on MRI of 
the brain and spinal cord.
In electrodiagnostic study, severe bilateral 
facial neuropathy with reduction in facial nerve 
compound muscle action potentials (CMAP) 
amplitude and severe denervation in needle 
electromyography (EMG) was present. Also in 
lower limbs, low amplitude sural sensory nerve 
action potential (SNAP) and low amplitude with 
mild reduction in conduction velocity of deep 
peroneal and tibial nerves CMAP were evident. 
There was not any evidence of conduction block 
except for mild carpal tunnel syndrome (CTS) in 
the right side.
Bipolar needle EMG of bilateral facial 
innervated muscles (orbicularis oris, orbicularis 
ocoli, nasalis, and frontalis), trigeminal 
innervated muscles (temporalis and masseter) 
and hypoglossal (tongue) demonstrated florid 
denervation by the way of ample fibrillations 
(3/4), and positive sharp waves (3/4 for all).
Additionally, there was a reduction in the 
recruitment and interference pattern of motor 
units and chronic motor unit remodeling 
changes to these muscles. Their amplitudes, 
duration, and polyphasia were within chronic 
neurogenic range (MUAP duration 3-4 msec and 
MUAP amplitude 4-5 mV). The motor unit action 
potential (MUAP) characteristics  of cervical and 
thoracic innervated muscles were normal, with 
no obvious evidence of denervation, and no 
changes in motor unit morphology, interference, 
and recruitment patterns. In lower limbs, EMG 
demonstrated mild denervation by the way of a 
few fibrillations (1/4) and positive sharp waves 
(1/4) in distal muscles. There was a reduction in 
the recruitment and interference pattern of motor 
units and chronic motor unit remodeling changes 
to these muscles. Their amplitudes, duration, 
and polyphasia were within chronic neurogenic 
range. Thus, these studies were indicative of a 
severe ongoing on chronic denervating process 
of mainly cranial nerves and length dependent 
mild axonal neuropathy in the limbs.
Discussion
This patient was diagnosed as having type IV 
(FINNISH) FAP on the basis of clinical 
manifestations, positive amyloid deposition 
on biopsied tissues and electrophysiologic 
findings. Clinical features of FINNISH 
type FAP characterized with the combination 
of lattice corneal dystrophy and multiple cranial 
neuropathies (e.g., facial palsies, and bulbar 
weakness).4 Onset of symptoms is usually in the 
third decade of life. Over time, a mild generalized 
sensorimotor polyneuropathy develops.
Type IV amyloidosis is caused by mutations 
in the gelsolin gene. The resultant mutations 
and amino acid substitutions are felt to lead to a 
charge change on the protein, which may render 
Figure 1: Shows familial amyloid polyneuropathy (FAP) type 
IV (FINNISH) in a 27-year-old Iranian woman presented with 
severe bilateral facial muscles atrophy.
 Familial amyloid polyneuropathy type IV (finnish)
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the molecule resistant to proteases.2 We could 
not perform genetic testing for this patient due to 
technical unavailability for FAP diseases in our 
country.
In type IV FAP, cranial nerves are mainly 
affected by the disturbance of sympathetic 
nervous system and axonal sensorimotor 
peripheral polyneuropathy in advanced stages. 
The clinical electrophysiological patterns in our 
patient are similar to that of FINNISH families 
with cranial neuropathy and corneal lattice 
dystrophy.2
Biopsy of abdominal fat tissues has been 
commonly employed for the histological 
diagnosis of familial amyloidosis, including 
FAP. Amyloid deposits in a multifocal or diffuse 
pattern in ganglia and peripheral nerves. 
Nerve histopathology of the different forms of 
FAP is similar showing fiber-length-dependent 
polyneuropathy, loss of myelinated nerves, 
particularly small myelinated and unmyelinated 
nerve fibers.5 The deposits are located in the 
endoneurium and within blood vessel walls. 
Endoneurial amyloid deposits can be noxious to 
nerve fibers in several ways, including mechanical 
and toxic effects on nerve fibers and impairment 
of blood supply.5 These deposits encroach upon 
the nerve fibers resulting in axonal degeneration 
and segmental demyelination.2
As suspected from the clinical features and 
histopathology, electrophysiologic studies reveal 
abnormalities consistent with a generalized or 
multifocal axonal sensorimotor polyneuropathy.4
SNAPs are diminished in amplitude and are 
normal or only mildly prolonged in latency or 
slow in conduction velocity. CMAPs can show 
similar findings in long-standing disease. Some 
forms of FAP are associated with carpal tunnel 
syndrome. Electromyography can demonstrate 
fibrillation potentials and positive sharp waves 
in the more distal weak limb muscles along 
with decreased recruitment of polyphasic, long-
duration, large-amplitude MUAPs.2
With regard to treatment of FAP, liver 
transplantation has reportedly halted the 
progression of clinical manifestations. In recent 
years, many new therapeutic strategies have 
been proposed and several ongoing therapeutic 
trials involving, for instance, stabilizers of 
transthyretin tetramers (tafamidis and diflunisal) 
and gene therapies to suppress transthyretin 
expression.6
We reported the first type IV FAP (FINNISH) 
Iranian woman with neurological deficits, including 
rapidly progressive cranial neuropathies, mild 
sensorimotor axonal peripheral polyneuropathy, 
unilateral CTS, corneal lattice dystrophy, and 
orthostatic hypotension.
In 2010 Lüttmann RJ et al., reported the first 
German family with FINNISH type FAP. Their 
youngest, clinically symptomatic family member 
was 26 years old. All patients suffered from an 
often asymmetric but not severe facial palsy. The 
disease took a slow chronic progressive course.4 
In comparison, our case presented with rapidly 
progressive and severe clinical presentation, 
especially in the cranial region.
In the more advanced stages of the disease, 
most patients showed grossly enlarged 
protuberant lips and the clinical finding of cutis 
laxa. It is characterized by loose skin, which 
causes the patients to look older than their age.7 
Our patient showed loose facial skin, mostly in 
the lower eyelid, but we did not find clinically 
relevant cutis laxa in other parts.
Conclusion
The authors conclude that in any case of 
symptomatic progressive multiple cranial 
nerves involvement and electrodiagnostic 
evidence of polyneuropathy, FAP should be 
considered as differential diagnosis. Based on 
high accuracy of abdominal fat, rectal or nerve 
tissue histopathology, we encourage biopsies in 
countries where genetic testing is not available.
This case highlights one of the rare conditions 
causing neuropathy, presenting mainly with 
facial muscle wasting.
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